Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMEHNASDAQ:MRTXNASDAQ:RDNTNASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMEHApollo Medical$39.79$28.86▼$43.12$2.38B1.04166,711 shs313,900 shsMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/ARDNTRadNet$55.54+0.5%$53.19$45.00▼$93.65$4.18B1.46684,154 shs62,460 shsTMDXTransMedics Group$128.45-0.1%$93.03$55.00▼$177.37$4.33B1.911.35 million shs212,811 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMEHApollo Medical0.00%0.00%0.00%0.00%0.00%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%RDNTRadNet-2.45%-4.77%+8.35%-4.01%-6.93%TMDXTransMedics Group+0.07%+6.03%+42.61%+78.34%-9.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMEHApollo MedicalN/AN/AN/AN/AN/AN/AN/AN/AMRTXMirati Therapeutics0.3562 of 5 stars0.00.00.04.70.00.00.6RDNTRadNet4.3382 of 5 stars3.73.00.04.63.52.50.0TMDXTransMedics Group1.981 of 5 stars1.43.00.00.03.42.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMEHApollo Medical 0.00N/AN/AN/AMRTXMirati Therapeutics 0.00N/AN/AN/ARDNTRadNet 3.40Buy$69.7525.59% UpsideTMDXTransMedics Group 2.82Moderate Buy$126.70-1.36% DownsideCurrent Analyst Ratings BreakdownLatest AMEH, TMDX, MRTX, and RDNT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025TMDXTransMedics GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$125.00 ➝ $130.005/9/2025TMDXTransMedics GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$105.00 ➝ $125.004/29/2025TMDXTransMedics GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$90.00 ➝ $105.004/23/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/11/2025RDNTRadNetTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$88.00 ➝ $74.003/26/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/24/2025RDNTRadNetBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$74.00 ➝ $60.003/11/2025TMDXTransMedics GroupCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$104.00 ➝ $104.003/5/2025RDNTRadNetRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$85.00 ➝ $65.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMEHApollo Medical$1.14B0.00N/A32.51$9.60 per share0.00MRTXMirati Therapeutics$12.44M331.01N/AN/A$17.31 per share3.39RDNTRadNet$1.87B2.23$2.95 per share18.81$11.79 per share4.71TMDXTransMedics Group$488.23M8.90$0.24 per share530.08$4.20 per share30.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMEHApollo Medical$45.17M$1.0040.820.001.153.56%9.90%5.51%N/AMRTXMirati Therapeutics-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/ARDNTRadNet$3.04M-$0.43N/A104.79N/A-0.25%4.29%1.45%8/5/2025 (Estimated)TMDXTransMedics Group-$25.03M$1.36136.3289.82N/A8.14%18.74%4.39%7/30/2025 (Estimated)Latest AMEH, TMDX, MRTX, and RDNT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025TMDXTransMedics Group$0.29$0.70+$0.41$0.70$123.39 million$143.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMEHApollo MedicalN/AN/AN/AN/AN/AMRTXMirati TherapeuticsN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/ATMDXTransMedics GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMEHApollo Medical0.352.352.35MRTXMirati TherapeuticsN/A7.547.40RDNTRadNet0.892.162.16TMDXTransMedics Group2.428.207.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMEHApollo Medical35.88%MRTXMirati TherapeuticsN/ARDNTRadNet77.90%TMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipAMEHApollo Medical8.46%MRTXMirati Therapeutics3.26%RDNTRadNet5.12%TMDXTransMedics Group7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMEHApollo Medical1,36258.28 million53.35 millionOptionableMRTXMirati Therapeutics58770.15 million67.86 millionOptionableRDNTRadNet8,97075.03 million70.24 millionOptionableTMDXTransMedics Group21033.82 million31.21 millionOptionableAMEH, TMDX, MRTX, and RDNT HeadlinesRecent News About These CompaniesBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Investors to Reach OutMay 29 at 10:00 AM | accessnewswire.comSpotlight on TransMedics Group Inc Top Companies in the NasdaqMay 29 at 6:13 AM | kalkinemedia.comKuehn Law Encourages Investors of TransMedics Group, Inc. to Contact Law FirmMay 27 at 8:32 PM | prnewswire.comTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 27 at 4:05 PM | prnewswire.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Stockholders to Reach OutMay 27 at 10:00 AM | accessnewswire.comGF Fund Management CO. LTD. Purchases Shares of 23,035 TransMedics Group, Inc. (NASDAQ:TMDX)May 27 at 5:26 AM | marketbeat.comMackenzie Financial Corp Buys 349,403 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)May 27 at 5:15 AM | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)May 27 at 4:56 AM | marketbeat.comProShare Advisors LLC Has $627,000 Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)May 27 at 4:12 AM | marketbeat.comAmeriprise Financial Inc. Has $6.10 Million Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)May 26 at 3:20 AM | marketbeat.comAnalysts Set TransMedics Group, Inc. (NASDAQ:TMDX) PT at $126.70May 26 at 2:25 AM | americanbankingnews.comBronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Stockholders to ConnectMay 25, 2025 | accessnewswire.comPacific Point Advisors LLC Acquires New Position in TransMedics Group, Inc. (NASDAQ:TMDX)May 25, 2025 | marketbeat.comVoloridge Investment Management LLC Sells 20,471 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)May 25, 2025 | marketbeat.comSquarepoint Ops LLC Sells 43,846 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)May 25, 2025 | marketbeat.comTransMedics Group, Inc. (NASDAQ:TMDX) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 25, 2025 | marketbeat.comTransMedics Group, Inc. (NASDAQ:TMDX) Director David Weill Sells 732 SharesMay 24, 2025 | insidertrades.comPalisades Investment Partners LLC Has $9.98 Million Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)May 24, 2025 | marketbeat.comNomura Holdings Inc. Acquires Shares of 7,357 TransMedics Group, Inc. (NASDAQ:TMDX)May 24, 2025 | marketbeat.comReasons to Retain TransMedics Stock in Your Portfolio for NowMay 23, 2025 | zacks.comTransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the InvestigationMay 22, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum3 Mid-Cap Medical Stocks Outperforming the MarketBy Ryan Hasson | May 6, 2025View 3 Mid-Cap Medical Stocks Outperforming the MarketAMEH, TMDX, MRTX, and RDNT Company DescriptionsApollo Medical NASDAQ:AMEHApollo Medical Holdings, Inc., a physician-centric technology-powered healthcare company, provides medical care services in the United States. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients in California. The company was incorporated in 1985 and is headquartered in Alhambra, California.Mirati Therapeutics NASDAQ:MRTXMirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.RadNet NASDAQ:RDNT$55.54 +0.25 (+0.45%) As of 11:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.TransMedics Group NASDAQ:TMDX$128.44 -0.18 (-0.14%) As of 11:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? CrowdStrike Stock Slips: Analyst Downgrades Before Earnings AutoZone Stock to Cross $4400 This Year: This Is Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
